MCSeres Therapeutics, Inc. MCRB · NASDAQ
$1.98 -6.60% (-$0.14)
- Market cap
- $19.7M
- Enterprise value
- $60.7M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- 10.5x
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -90.0%
- Bruto marža
- 82.6%
- Neto marža
- -1,192.9%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -
- Beta
- 0.22
- Free float
- 76.4%
O podjetju
Seres Therapeutics, Inc. (MCRB) is a biotechnology company focused on developing microbiome-based therapies. Their research and development efforts are centered around leveraging natural bacterial communities inhabiting the human body to treat various diseases. Seres Therapeutics particularly targets areas of the gastrointestinal tract, infectious diseases, and immune disorders. The company is developing microbiome-based therapeutics aimed at restoring the health of microbial communities in patients. Their research focuses on identifying and selecting appropriate bacterial strains and their application in treating specific diseases. Shares of Seres Therapeutics, Inc. (MCRB) could be suitable for investors seeking investments in the biotechnology sector with a focus on developing innovative microbiome-based drugs.
Sector
Healthcare
Industry
Biotechnology
CEO
Richard N. Kender
Employees
66
Headquarters
Cambridge
Vrednotenje
Je današnja cena primerna?
- Na kaj bodite pozorni: Cena delnice je nad Bulios Fair Price.
Rast in ocene
Ali podjetje raste in kaj sledi?
- Na kaj bodite pozorni: Napovedi dobička ni dosegla 4-krat v zadnjih 8 četrtletjih.
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
- Na kaj bodite pozorni: Podjetje je v zadnjih 12 mesecih poslovalo z izgubo.
Finančno zdravje
Ali zmore svoj dolg?
- Na kaj bodite pozorni: V testu finančnega zdravja (Piotroski) izpolni le 3 od 9 točk.
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
- Kaj govori v prid: Cena niha manj kot trg (beta 0,22).
Izkazi
Vse številke